核心临床分子诊断市场－全球产业规模、份额、趋势、机会及预测（依产品类型、技术、应用、最终用户、地区及竞争格局划分，2021-2031年）

全球核心临床分子诊断市场预计将从 2025 年的 66.5 亿美元成长到 2031 年的 117.5 亿美元，复合年增长率为 9.95%。

此领域涵盖用于分析遗传物质（例如DNA和RNA）的检测系统和分析方法，旨在检测对疾病诊断、风险评估和治疗监测至关重要的生物标记。推动该领域成长的主要因素是慢性病和感染疾病）的日益流行，这使得高精度的检测方法对于有效管理患者照护至关重要。此外，全球人口老化以及向预防性医疗保健模式的策略转变，而非暂时的技术趋势，才是推动对这些诊断工具需求的重要因素。

然而，由于复杂且高成本的检测核准和合规法规结构，市场面临许多障碍。严格的临床证据和上市后监控标准常常导致产品上市延迟，并对企业资源造成巨大压力。根据欧洲医疗技术协会（MedTech Europe）预测，到2024年，这些日益严格的监管将使体外诊断试剂生产商的维护和再认证相关成本增加70%。这种财务压力对分子诊断解决方案的持续成长和普及构成了重大挑战。

市场驱动因素

PCR和次世代定序（NGS）平台的技术进步正透过提高检测灵敏度和降低定序成本，从根本上改变全球核心临床分子诊断市场。次世代定序的引入实现了多个基因的同时分析，这对于复杂诊断和精准医疗应用至关重要。高通量系统的快速工业化应用凸显了这个转变。根据Illumina公司于2024年2月发布的“2023财年第四季度及全年财务业绩报告”，该公司在该财年共交付了352台旗舰产品NovaSeq X测序仪。这些先进的平台使临床检查室能够更有效率地处理大量基因组数据，直接满足了常规分子检测流程中对速度的迫切需求。

同时，癌症和遗传性疾病发生率的上升是市场扩张的主要驱动力，因此亟需强而有力的早期检测解决方案。随着全球癌症负担的加重，医疗服务提供者越来越依赖分子谱分析来识别生物标记物，从而指导标靶治疗方案的发展。世界卫生组织（WHO）于2024年2月发布的《全球癌症负担》报告预测，2022年全球新增癌症病例将达到约2,000万例。为了满足日益增长的临床需求，儘管面临监管方面的挑战，製造商仍在加速推动创新研发。 MedTech Dive网站2024年1月发表的一篇报导《FDA在2023年核准了创纪录数量的新医疗设备》报道称，美国FDA在2023年核准了124种新的医疗设备，证实了诊断领域强劲的研发势头。

市场挑战

核心临床分子诊断市场正受到日益复杂且高成本的法规环境的严重限制。随着监管机构对临床证据和上市后监测的要求日益严格，诊断设备开发商的财务和营运负担也随之加重。这种日益严格的监管迫使企业将大量资金和人力资源从研发活动中转移出来，只是为了满足监管要求。因此，新诊断测试的开发週期不断延长，高昂的核准成本阻碍了专业测试的商业化，有效地抑制了创新并限制了产品系列的扩展。

这种不利局面直接阻碍了市场成长，降低了新技术在关键地区的吸引力。製造商越来越不愿意优先考虑核准时间难以预测的市场，导致新产品上市数量减少。根据欧洲医疗技术协会（MedTech Europe）发布的《2024年报告》，选择欧盟作为主要上市地区的领先体外诊断试剂製造商数量较先前的监管规定下降了40%。产品供应减少和最新诊断技术取得延迟正在损害市场潜力，迫使企业为了降低合规风险而放弃扩大策略。

市场趋势

分散式即时就地检验的兴起正在迅速重塑市场格局，将诊断能力从集中式基础设施转移到更贴近患者的场所。医疗系统正优先考虑这一趋势，以缩短关键感染疾病管理中检测结果的等待时间，使医生能够即时做出治疗决策，而无需承受将检体运送到中心检查室带来的物流延误。这些快速检测平台的日益普及也反映在近期的财务揭露中。在丹纳赫公司于2024年1月发布的「2023年第四季及全年财务业绩」中，其Cefeed业务部门报告称，该季度呼吸道检测以金额为准约为6.5亿美元，远超公司最初内部预测的3.5亿美元。

同时，液态生物检体在非侵入性肿瘤学领域的应用日益广泛，透过简单的抽血即可进行基因组分析，而非传统的侵入性组织切片检查，从而为癌症管理树立了新的范式。这种调查方法克服了重复手术取样带来的临床风险和时间安排上的挑战，并有助于对患者进行长期监测和微量残存疾病的检测。随着医疗机构将这些解决方案纳入日常诊疗流程，市场接受度正稳步提升。根据Guardant Health于2024年2月发布的“2023财年第四季度及全年财务业绩报告”，该公司临床检测量上年度39%，表明医疗机构对非侵入性诊断工具的偏好发生了显着转变。

目录

第一章概述

第二章调查方法

第三章执行摘要

第四章：客户评价

第五章 全球核心临床分子诊断市场展望

• 市场规模及预测
  • 按金额
• 市占率及预测
  • 依产品类型（仪器、试剂和试剂盒、软体和服务）
  • 透过技术（PCR、核酸定序、萤光原位杂合反应（FISH）、其他）
  • 依应用领域（感染疾病、遗传性疾病、癌症筛检等）
  • 按最终用户划分（医院和诊断检查室、学术和研究机构、製药和生物技术公司、受託研究机构(CRO) 等）
  • 按地区
  • 按公司（2025 年）
• 市场地图

6. 北美核心临床分子诊断市场展望

• 市场规模及预测
• 市占率及预测
• 北美洲：国家分析
  • 我们
  • 加拿大
  • 墨西哥

7. 欧洲核心临床分子诊断市场展望

• 市场规模及预测
• 市占率及预测
• 欧洲：国家分析
  • 德国
  • 法国
  • 英国
  • 义大利
  • 西班牙

8. 亚太地区核心临床分子诊断市场展望

• 市场规模及预测
• 市占率及预测
• 亚太地区：国家分析
  • 中国
  • 印度
  • 日本
  • 韩国
  • 澳洲

9. 中东和非洲核心临床分子诊断市场展望

• 市场规模及预测
• 市占率及预测
• 中东和非洲：国家分析
  • 沙乌地阿拉伯
  • 阿拉伯聯合大公国
  • 南非

第十章 南美洲核心临床分子诊断市场展望

• 市场规模及预测
• 市占率及预测
• 南美洲：国家分析
  • 巴西
  • 哥伦比亚
  • 阿根廷

第十一章 市场动态

• 司机
• 任务

第十二章 市场趋势与发展

• 併购
• 产品发布
• 最新进展

第十三章 全球核心临床分子诊断市场：SWOT分析

第十四章：波特五力分析

• 产业竞争
• 新进入者的可能性
• 供应商电力
• 顾客权力
• 替代品的威胁

第十五章 竞争格局

• F. Hoffmann-La Roche Ltd.
• Danaher Corporation
• Abbott Laboratories
• Thermo Fisher Scientific Inc.
• QIAGEN NV
• Hologic Inc.
• bioMerieux SA
• Siemens Healthineers AG
• Becton, Dickinson and Company
• Agilent Technologies, Inc.

第十六章 策略建议

第十七章：关于研究公司及免责声明

The Global Core Clinical Molecular Diagnostics Market is projected to expand from USD 6.65 Billion in 2025 to USD 11.75 Billion by 2031, reflecting a CAGR of 9.95%. This sector comprises laboratory systems and assays that analyze genetic material, such as DNA and RNA, to detect biological markers essential for disease diagnosis, risk assessment, and therapeutic monitoring. Growth is largely driven by the rising prevalence of chronic conditions and infectious diseases, particularly cancer, which creates a critical need for high-precision testing methods to manage patient care effectively. Additionally, the aging global population and a strategic shift toward preventive healthcare models are significantly boosting demand for these diagnostic tools, distinct from temporary technological trends.

However, the market faces significant hurdles due to a complex and expensive regulatory framework regarding test approval and compliance. Rigorous standards for clinical evidence and post-market surveillance frequently delay product introductions and place a heavy strain on corporate resources. According to MedTech Europe, it was reported in 2024 that in vitro diagnostic manufacturers are experiencing a 70% increase in costs associated with maintenance and re-certification because of these intensified regulatory mandates. This financial pressure presents a substantial challenge to the sustained growth and accessibility of molecular diagnostic solutions.

Market Driver

Technological advancements in PCR and NGS platforms are fundamentally transforming the Global Core Clinical Molecular Diagnostics Market by improving test sensitivity and reducing sequencing costs. The implementation of next-generation sequencing enables the simultaneous analysis of multiple genes, which is vital for complex diagnostics and the application of precision medicine. This shift is highlighted by the rapid industrial adoption of high-throughput systems; according to Illumina's 'Financial Results for Fourth Quarter and Fiscal Year 2023' in February 2024, the company shipped 352 of its flagship NovaSeq X instruments during the fiscal year. These advanced platforms allow clinical laboratories to process massive volumes of genomic data more efficiently, directly meeting the critical need for speed in routine molecular testing workflows.

Concurrently, the rising incidence of cancer and genetic disorders serves as a primary catalyst for market expansion, necessitating robust solutions for early detection. As the global oncology burden increases, healthcare providers increasingly rely on molecular profiling to identify biomarkers that guide targeted treatment plans. According to the World Health Organization's 'Global Cancer Burden' release in February 2024, there were an estimated 20 million new cancer cases globally in 2022. To address this surging clinical demand, manufacturers are accelerating their innovation pipelines despite regulatory challenges; MedTech Dive's January 2024 article, 'FDA authorizes record number of new devices in 2023,' noted that the US FDA authorized 124 novel medical devices in 2023, underscoring the vibrant development activity within the diagnostic sector.

Market Challenge

The core clinical molecular diagnostics market is significantly constrained by an increasingly intricate and expensive regulatory environment. As authorities implement stricter mandates for clinical evidence and post-market surveillance, the financial and operational burdens on diagnostic developers have intensified. This regulatory rigor compels companies to divert substantial capital and personnel away from research and development activities solely to navigate compliance pathways. Consequently, development timelines for novel diagnostic assays are extended, and the high cost of approval discourages the commercialization of specialized tests, effectively stifling innovation and limiting portfolio expansion.

This burdensome landscape directly hampers market growth by making major regions less attractive for introducing new technologies. Manufacturers are increasingly hesitant to prioritize markets with unpredictable approval timelines, resulting in fewer new product launches. According to MedTech Europe in 2024, the number of large in vitro diagnostic manufacturers choosing the European Union as their primary launch geography dropped by 40% compared to previous regulatory directives. This contraction in product availability and delayed access to modern diagnostics undermines the market's potential as companies retreat from expansion strategies to mitigate compliance risks.

Market Trends

The shift toward Decentralized Point-of-Care Testing is actively restructuring the market by relocating diagnostic capabilities from centralized infrastructure to near-patient environments. This trend is prioritized by healthcare systems aiming to reduce turnaround times for critical infectious disease management, allowing physicians to make immediate therapeutic decisions without the logistical delays associated with core laboratory transport. The intensified utilization of these rapid platforms is reflected in recent financial disclosures; according to Danaher's 'Fourth Quarter and Full Year 2023 Results' in January 2024, the Cepheid business unit reported approximately $650 million in respiratory testing revenue for the quarter, a figure that significantly exceeded the company's original internal projection of $350 million.

Simultaneously, the expansion of Liquid Biopsy for Non-Invasive Oncology is establishing a new paradigm in cancer management by enabling genomic profiling through simple blood draws rather than invasive tissue biopsies. This methodology facilitates longitudinal patient monitoring and the detection of minimal residual disease, overcoming the clinical risks and scheduling difficulties associated with repeated surgical sampling. Market uptake of these solutions has been robust as providers integrate them into routine care; according to Guardant Health's 'Fourth Quarter and Full Year 2023 Financial Results' in February 2024, the company reported a 39% increase in clinical testing volume for the fiscal year, signaling a strong shift in provider preference toward these non-invasive diagnostic tools.

Key Market Players

• F. Hoffmann-La Roche Ltd.
• Danaher Corporation
• Abbott Laboratories
• Thermo Fisher Scientific Inc.
• QIAGEN N.V.
• Hologic Inc.
• bioMerieux SA
• Siemens Healthineers AG
• Becton, Dickinson and Company
• Agilent Technologies, Inc.

Report Scope

In this report, the Global Core Clinical Molecular Diagnostics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Core Clinical Molecular Diagnostics Market, By Product Type

• Instruments
• Reagents & Kits
• Software & Services

Core Clinical Molecular Diagnostics Market, By Technology

• PCR
• Nucleic Acid Sequencing
• Fluorescence In Situ Hybridization (FISH)
• Others

Core Clinical Molecular Diagnostics Market, By Application

• Infectious Disease
• Genetic Disorder
• Cancer Screening
• Others

Core Clinical Molecular Diagnostics Market, By End User

• Hospitals & Diagnostic Laboratories
• Academic & Research Institutions
• Pharmaceutical & Biotechnology Companies
• Contract Research Organizations (CROs)
• Others

Core Clinical Molecular Diagnostics Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Core Clinical Molecular Diagnostics Market.

Available Customizations:

Global Core Clinical Molecular Diagnostics Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Core Clinical Molecular Diagnostics Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Product Type (Instruments, Reagents & Kits, Software & Services)
  • 5.2.2. By Technology (PCR, Nucleic Acid Sequencing, Fluorescence In Situ Hybridization (FISH), Others)
  • 5.2.3. By Application (Infectious Disease, Genetic Disorder, Cancer Screening, Others)
  • 5.2.4. By End User (Hospitals & Diagnostic Laboratories, Academic & Research Institutions, Pharmaceutical & Biotechnology Companies, Contract Research Organizations (CROs), Others)
  • 5.2.5. By Region
  • 5.2.6. By Company (2025)
• 5.3. Market Map

6. North America Core Clinical Molecular Diagnostics Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Product Type
  • 6.2.2. By Technology
  • 6.2.3. By Application
  • 6.2.4. By End User
  • 6.2.5. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Core Clinical Molecular Diagnostics Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Product Type
      • 6.3.1.2.2. By Technology
      • 6.3.1.2.3. By Application
      • 6.3.1.2.4. By End User
  • 6.3.2. Canada Core Clinical Molecular Diagnostics Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Product Type
      • 6.3.2.2.2. By Technology
      • 6.3.2.2.3. By Application
      • 6.3.2.2.4. By End User
  • 6.3.3. Mexico Core Clinical Molecular Diagnostics Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Product Type
      • 6.3.3.2.2. By Technology
      • 6.3.3.2.3. By Application
      • 6.3.3.2.4. By End User

7. Europe Core Clinical Molecular Diagnostics Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Product Type
  • 7.2.2. By Technology
  • 7.2.3. By Application
  • 7.2.4. By End User
  • 7.2.5. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Core Clinical Molecular Diagnostics Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Product Type
      • 7.3.1.2.2. By Technology
      • 7.3.1.2.3. By Application
      • 7.3.1.2.4. By End User
  • 7.3.2. France Core Clinical Molecular Diagnostics Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Product Type
      • 7.3.2.2.2. By Technology
      • 7.3.2.2.3. By Application
      • 7.3.2.2.4. By End User
  • 7.3.3. United Kingdom Core Clinical Molecular Diagnostics Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Product Type
      • 7.3.3.2.2. By Technology
      • 7.3.3.2.3. By Application
      • 7.3.3.2.4. By End User
  • 7.3.4. Italy Core Clinical Molecular Diagnostics Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Product Type
      • 7.3.4.2.2. By Technology
      • 7.3.4.2.3. By Application
      • 7.3.4.2.4. By End User
  • 7.3.5. Spain Core Clinical Molecular Diagnostics Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Product Type
      • 7.3.5.2.2. By Technology
      • 7.3.5.2.3. By Application
      • 7.3.5.2.4. By End User

8. Asia Pacific Core Clinical Molecular Diagnostics Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Product Type
  • 8.2.2. By Technology
  • 8.2.3. By Application
  • 8.2.4. By End User
  • 8.2.5. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Core Clinical Molecular Diagnostics Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Product Type
      • 8.3.1.2.2. By Technology
      • 8.3.1.2.3. By Application
      • 8.3.1.2.4. By End User
  • 8.3.2. India Core Clinical Molecular Diagnostics Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Product Type
      • 8.3.2.2.2. By Technology
      • 8.3.2.2.3. By Application
      • 8.3.2.2.4. By End User
  • 8.3.3. Japan Core Clinical Molecular Diagnostics Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Product Type
      • 8.3.3.2.2. By Technology
      • 8.3.3.2.3. By Application
      • 8.3.3.2.4. By End User
  • 8.3.4. South Korea Core Clinical Molecular Diagnostics Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Product Type
      • 8.3.4.2.2. By Technology
      • 8.3.4.2.3. By Application
      • 8.3.4.2.4. By End User
  • 8.3.5. Australia Core Clinical Molecular Diagnostics Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Product Type
      • 8.3.5.2.2. By Technology
      • 8.3.5.2.3. By Application
      • 8.3.5.2.4. By End User

9. Middle East & Africa Core Clinical Molecular Diagnostics Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Product Type
  • 9.2.2. By Technology
  • 9.2.3. By Application
  • 9.2.4. By End User
  • 9.2.5. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Core Clinical Molecular Diagnostics Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Product Type
      • 9.3.1.2.2. By Technology
      • 9.3.1.2.3. By Application
      • 9.3.1.2.4. By End User
  • 9.3.2. UAE Core Clinical Molecular Diagnostics Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Product Type
      • 9.3.2.2.2. By Technology
      • 9.3.2.2.3. By Application
      • 9.3.2.2.4. By End User
  • 9.3.3. South Africa Core Clinical Molecular Diagnostics Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Product Type
      • 9.3.3.2.2. By Technology
      • 9.3.3.2.3. By Application
      • 9.3.3.2.4. By End User

10. South America Core Clinical Molecular Diagnostics Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Product Type
  • 10.2.2. By Technology
  • 10.2.3. By Application
  • 10.2.4. By End User
  • 10.2.5. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Core Clinical Molecular Diagnostics Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Product Type
      • 10.3.1.2.2. By Technology
      • 10.3.1.2.3. By Application
      • 10.3.1.2.4. By End User
  • 10.3.2. Colombia Core Clinical Molecular Diagnostics Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Product Type
      • 10.3.2.2.2. By Technology
      • 10.3.2.2.3. By Application
      • 10.3.2.2.4. By End User
  • 10.3.3. Argentina Core Clinical Molecular Diagnostics Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Product Type
      • 10.3.3.2.2. By Technology
      • 10.3.3.2.3. By Application
      • 10.3.3.2.4. By End User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Core Clinical Molecular Diagnostics Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. F. Hoffmann-La Roche Ltd.
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Danaher Corporation
• 15.3. Abbott Laboratories
• 15.4. Thermo Fisher Scientific Inc.
• 15.5. QIAGEN N.V.
• 15.6. Hologic Inc.
• 15.7. bioMerieux SA
• 15.8. Siemens Healthineers AG
• 15.9. Becton, Dickinson and Company
• 15.10. Agilent Technologies, Inc.

16. Strategic Recommendations

17. About Us & Disclaimer